Company Overview: BAYRY

Upcoming Projects (BAYRY)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (BAYRY)

Discussing OASIS 1 and 2 Phase III studies of Bayer's elinzanetant in treating VMS associated with menopause
Ticker: BAYRY
Executed On: Feb 12, 2024 at 05:45 PM EST
Discussing Kerendia (finerenone) for the prevention of heart and kidney complications in chronic kidney disease (CKD) associated with type 2 diabetes
Tickers: BAYRY, BAYN.XFRA
Executed On: Mar 11, 2022 at 04:00 PM EST

Upcoming & Overdue Catalysts (BAYRY)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (BAYRY)

Between second half 2017 and first half 2018, Intellia Therapeutics (NTLA) will start initial new drug application-based (IND) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy using from CRISPR/Cas9 gene revision concept
Tickers: NTLA, CRSP, BAYRY
Occurred on: Oct 18, 2018
Results of Factor Xa inhibitor rivaroxaban (Xarelto) from studies COMMANDER HF and MARINER studies presented at ESC Congress 2018
Ticker: BAYRY
Occurred on: Aug 27, 2018
Intellia Therapeutics (NTLA) set to commence non-human primate (NHP) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy developed with Regeneron based on the CRISPR/Cas9 genetic editing system in 2017
Tickers: NTLA, CRSP, BAYRY, REGN
Occurred on: May 01, 2018
NTLA in vivo Hepatitis B Virus (HBV) program by Intellia, based on CRISPR/Cas9 genetic editing system, set for HBV animal trials in 2017
Tickers: NTLA, BAYRY, CRSP
Occurred on: May 01, 2018
CRISPR (CRSP) Therapeutics preparing to file clinical trial authorization application (CTA) in Europe by end of 2017 for CRISPR/Cas9 gene editing product to treat beta-thalassemia, a disorder causing hemoglobin deficiency
Tickers: CRSP, BAYRY
Occurred on: Dec 07, 2017
Bayer's (BAYRY) Stivarga (Regorafenib) Approved for Expanded Indication in Treatment of Patients with Liver Cancer Who Have Been Previously Treated with Sorafenib (Nexavar)
Ticker: BAYRY
Occurred on: Apr 27, 2017
CRISPR and Casebia by Bayer (BAYRY) obtain rights to MaxCyte's cell engineering platform to create therapies for hemoglobin disorders and immunodeficiency
Tickers: CRSP, BAYRY
Occurred on: Mar 14, 2017
Bayer (BAYRY) Releases Phase 3b PIONEER AF-PCI Results Evaluating Xarelto in Patients with Irregular Heartbeat After Percutaneous Coronary Intervention at the American Heart Association Scientific Sessions 2016
Ticker: BAYRY
Occurred on: Nov 14, 2016
Bayer (BAYRY) Announces Regulatory Submission of Regorafenib in Second-Line Treatment of Liver Cancer in U.S, Europe, and Japan
Ticker: BAYRY
Occurred on: Nov 07, 2016
Ionis Pharma (IONS) to finish Phase 2 study of IONIS-FXIrx administered to Patients with End-Stage Renal Disease on Hemodialysis in Fall 2016
Tickers: IONS, BAYRY
Occurred on: Nov 01, 2016
Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Occurred on: Oct 12, 2016
First Patient Enrolled in Bayer (BAYRY) and Merck's (MRK) Phase 3 VICTORIA Trial Assessing Vericiguat in Chronic Heart Failure Without Reduced Ejection Fraction
Tickers: BAYRY, MRK
Occurred on: Sep 28, 2016
Bayer's (BAYRY) Five-Year Intrauterine Contraceptive Kyleena Approved by FDA
Ticker: BAYRY
Occurred on: Sep 19, 2016
Bayer (BAYRY) Plans to Launch Five-Year Intrauterine System Kyleena in U.S in October 2016 After FDA Approval
Ticker: BAYRY
Occurred on: Sep 19, 2016

Strategic Initiatives (BAYRY)

Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Announcement Date: Oct 12, 2016
Bayer (BAYRY) Announces 5-Year Multi-Target Partnership with Evotec (EVOTF) to Develop Candidates for Kidney Disease
Tickers: BAYRY, EVOTF
Announcement Date: Sep 21, 2016

BAYRY Overview